NEW YORK, May 19, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the expansion of its intellectual property protection surrounding its CD34 Cell Program in which it is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted. AMR-001 is the Company's most clinically advanced product candidate in its CD34 Cell Program and is being developed to treat damaged heat muscle following a heart attack.
NeoStem Expands Patent Portfolio With Grant Of Two European Patents
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts